iBio, Inc. Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2013. The request references “2012 Q3,” but the filing is for the third quarter of fiscal 2013. The filing was signed May 20, 2013.
Business Context
iBio is a biotechnology company commercializing plant-based protein expression technologies, including the iBioLaunch and iBioModulator platforms, and developing vaccine and therapeutic candidates. Its strategy emphasizes licensing, collaborations, and partner-funded development. The company operates in one U.S.-based business segment.
Financial Performance and Position
| Metric | Three Months Ended March 31, 2013 | Three Months Ended March 31, 2012 |
|---|---|---|
| Revenue | $0 | $371,755 |
| Operating expenses | $1.86 million | $2.55 million |
| Operating loss | $1.86 million | $2.18 million |
| Other income (expense) | $102,120 | ($916,928) |
| Net loss | $1.76 million | $3.10 million |
| Basic and diluted loss per share | $0.04 loss | $0.07 loss |
| Metric | Nine Months Ended March 31, 2013 | Nine Months Ended March 31, 2012 |
|---|---|---|
| Revenue | $390,186 | $925,935 |
| Research and development expense | $2.46 million | $3.93 million |
| General and administrative expense | $3.29 million | $4.18 million |
| Operating loss | $5.37 million | $7.18 million |
| Net loss | $4.88 million | $4.31 million |
| Net cash used in operating activities | $3.94 million | $4.97 million |
Margins were not meaningful because revenue was zero in the current quarter and the company remained loss-making. The nine-month operating loss exceeded revenue by approximately $5.0 million. No income tax expense was recorded because the company maintained a valuation allowance against its deferred tax assets.
At March 31, 2013, cash was $1.53 million, compared with $5.62 million at June 30, 2012. Total assets were $4.98 million and stockholders’ equity was $2.30 million. Total liabilities were $2.68 million, including $2.42 million of accounts payable and a $16,668 warrant derivative liability. The filing does not identify conventional interest-bearing debt as a material balance-sheet item.
Material Changes Versus Prior Comparable Period
- Third-quarter revenue fell to zero from $371,755 because revenue recognition under the FioCruz yellow-fever vaccine services arrangement was suspended while the parties negotiated a revised work plan.
- Nine-month revenue declined approximately 58% to $390,186, with revenue recognized only in the first quarter of fiscal 2013.
- Research and development expense decreased approximately 52% in the quarter and 37% for the nine-month period, primarily because certain Fraunhofer projects were completed and related FioCruz subcontracting activity ceased pending revised agreements.
- General and administrative expense was essentially flat in the quarter and declined approximately 21% for the nine-month period, partly because of lower share-based compensation.
- The quarterly net loss improved primarily because the warrant derivative liability generated $108,832 of other income versus $918,428 of other expense in the prior-year quarter. This was a non-cash valuation effect.
- Cash used in operations declined by approximately $1.03 million for the nine-month period, but the company had no financing cash inflows during the period versus $9.04 million of equity financing in the prior-year period.
- Approximately 4.2 million warrants with anti-dilution provisions were scheduled to expire in August 2013, and the derivative liability declined to $16,668 from $519,725 at June 30, 2012.
Liquidity, Outlook, Risks, and Unusual Items
- Management stated that March 31 cash of approximately $1.5 million was expected to fund operations only through the end of the second calendar quarter of 2013.
- On April 26, 2013, the company raised approximately $3.8 million net through the issuance of 8.925 million common shares and warrants to purchase up to 3.57 million additional shares. Management estimated that this financing, together with existing cash, would support operations through the end of the fourth calendar quarter of 2013.
- The financing substantially used the company’s available Form S-3 capacity, limiting the ability to conduct additional registered offerings before approximately April 2014 unless the stock price or public float increases materially. Additional financing may require private placement or Form S-1 offerings and could dilute shareholders.
- The company disclosed substantial doubt about its ability to continue as a going concern because of recurring losses, negative operating cash flow, limited cash, and dependence on future financing or collaboration proceeds.
- On April 18, 2013, NYSE MKT notified the company that it was not in compliance with a continued-listing standard related to losses and financial resources. The company submitted a compliance plan and was awaiting the Exchange’s response. Failure to regain compliance could result in delisting and reduced trading liquidity.
- The Technology Transfer Agreement with Fraunhofer requires aggregate non-refundable payments of $10 million in installments through December 2014, plus royalties and minimum annual payments. The companies were negotiating a further amendment, and work efforts had been temporarily reduced.
- The company entered a new February 2013 collaboration with Caliber Biotherapeutics for an oncology-related biosimilar candidate and continued its alliance with GE Healthcare. These arrangements had not yet produced material reported revenue in the quarter.
- The ATM equity facility established in January 2013 was terminated on April 26, 2013 without any stock sales. Approximately $121,000 of related costs had already been expensed.
Investor Verification Items
- Confirm the status and terms of the FioCruz work-plan amendment and whether service revenue recognition has resumed.
- Verify post-quarter-end cash balances, quarterly cash burn, and the duration of funding provided by the April equity offering.
- Assess the likelihood and terms of additional financing, including potential shareholder dilution and the company’s restricted Form S-3 capacity.
- Monitor NYSE MKT compliance proceedings and the risk of delisting.
- Review the outstanding Fraunhofer obligations, proposed Technology Transfer Agreement amendment, and approximately $2.2 million payable to Fraunhofer at March 31, 2013.
- Track warrant exercises, anti-dilution adjustments, expirations, and the potential impact of approximately 21.0 million outstanding warrants and 6.76 million stock options on future dilution.